Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older, of any gender
- People diagnosed with certain types of B-cell lymphoma, including diffuse large B-cell lymphoma (several subtypes), follicular lymphoma, mantle cell lymphoma, or related aggressive lymphoma conditions (confirm specific diagnosis eligibility with trial site)
- People who have already received at least two rounds of standard treatment and either did not achieve remission or their condition returned after remission
- People who have at least one measurable area of disease visible on a PET-CT or CT scan, meeting specific size requirements (confirm with trial site)
- People whose lymphoma cells have tested positive for a protein called CD19
- People whose liver, kidney, and heart are functioning adequately, and whose blood oxygen levels are sufficient without extra oxygen support (confirm specific test thresholds with trial site)
- People with a performance status rating of 0–2 on the ECOG scale, meaning they are able to carry out at least some daily activities (confirm with trial site)
- People with an expected survival of more than 3 months
- People of childbearing potential who agree to use reliable contraception from the time of signing consent until 2 years after receiving the study treatment
Who may not be able to join:
- People who have had a significant brain or nervous system condition in the 6 months before screening, such as stroke, epilepsy, severe brain injury, dementia, or Parkinson's disease
- People who have or have had a cancer other than B-cell lymphoma
- People who received a vaccine or a treatment targeting B-cells within 4 weeks before screening
- People with a systemic autoimmune disease or a condition that weakens the immune system
- People who have had moderate to severe graft-versus-host disease (a complication sometimes seen after stem cell transplants) within the 4 weeks before screening
- People with significant heart conditions such as angina, heart attack, heart failure, or serious irregular heartbeat
- People with a history of severe allergic reactions to any drugs or ingredients used in this study
- People with active hepatitis B, hepatitis C, HIV, or syphilis
- People with an active infection currently requiring intravenous antibiotics or hospital care
- People who are pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86-0551-62284476
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Adverse events; The persistence, accumulation, and migration of anti-CD19 gene injection
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.